noraminophenazone
an antispasmodic
Networked: 4
relevant articles (0 outcomes,
1 trials/studies)
Bio-Agent Context: Research Results
Experts
Related Diseases
1. | Hyperthermia
09/01/2006
- " Noraminophenazone blocked the development of urocortin 3-induced hyperthermia, or attenuated it when the hyperthermia was already present. " 04/27/2000
- " An intramuscular injection of noraminophenazone (a cyclooxygenase inhibitor) abolished the PACAP-38-induced hyperthermia. " 09/01/2006
- " In order to study the possible role of prostaglandins, the animals were treated with either a urocortin together with the pyrazolone derivative noraminophenazone to inhibit the action of cyclooxygenase in initiating hyperthermia, or with noraminophenazone 30 min following urocortin administration to act on existing hyperthermia. " 06/01/2014
- " For an investigation of the possible role of receptors in mediating hyperthermia, the animals were treated simultaneously with CRF 9-41 and antalarmin, a CRH1 receptor inhibitors, astressin 2B, a CRH2 receptor antagonist, haloperidol a dopamine receptor antagonist, atropine a muscarinic cholinergic receptor antagonist, noraminophenazone a cyclooxygenase inhibitor or isatin, a prostaglandin receptor antagonist. "
|
2. | Drug Hypersensitivity (Drug Allergy)
|
|
Related Drugs and Biologics
Related Therapies and Procedures